Annexon, Inc. ANNX · Stock Open Annexon, Inc. in new tab
Annexon, Inc. Analysis (ANNX)
Is Annexon, Inc. a good investment? Annexon, Inc. (ANNX) is currently trading at 3.92 USD. Market analysts have a consensus price target of 15.29 USD. This suggests a potential upside from current levels.
Earnings Schedule: Annexon, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -1.08.
Investor FAQ
Does Annexon, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Annexon, Inc.?
Annexon, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -1.13.
Company Profile
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Community Discussion